Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; magnesium stearate; povidone; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; purified talc; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; povidone; purified talc; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.366 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; povidone; colloidal anhydrous silica; titanium dioxide; calcium hydrogen phosphate dihydrate; purified talc; hypromellose; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 172.683 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; povidone; purified talc; magnesium stearate; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.244 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; sodium starch glycollate type a; macrogol 400; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: lactose; hypromellose; microcrystalline cellulose; magnesium stearate; polysorbate 80; titanium dioxide; macrogol 400; allura red ac aluminium lake; brilliant blue fcf aluminium lake - seasonique is indicated for use as an oral contraceptive.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - cloquintocet-mexyl; topramezone; liquid hydrocarbon - suspoemulsion - cloquintocet-mexyl acetate active 60.0 g/l; topramezone active 60.0 g/l; liquid hydrocarbon solvent other 200.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - quetiapine fumarate -

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - quetiapine fumarate 115.122mg equivalent to 100 mg quetiapine - film coated tablet - 100 mg - active: quetiapine fumarate 115.122mg equivalent to 100 mg quetiapine excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry yellow 03b82923 povidone purified talc sodium starch glycolate - acute and chronic psychoses, including schizophrenia.

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine - film coated tablet - 150 mg - active: quetiapine fumarate 172.683mg equivalent to 150 mg quetiapine excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry yellow 03b82924 povidone purified talc sodium starch glycolate - acute and chronic psychoses, including schizophrenia.